Journal
CANCER PREVENTION RESEARCH
Volume 9, Issue 9, Pages 758-765Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-15-0434
Keywords
-
Categories
Funding
- NIH [R01 CA120719]
- French National Cancer Institute (Institut National du Cancer
- INCA) [2009-139]
- European Commission (DG-SANCO)
- International Agency for Research on Cancer
- Danish Cancer Society (Denmark)
- Ligue Contre le Cancer (France)
- Institut Gustave Roussy (France)
- Mutuelle Generale de l'Education Nationale (France)
- Institut National de la Sante et de la Recherche Medicale (INSERM) (France)
- Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ) (Germany)
- Federal Ministry of Education and Research (Germany)
- Hellenic Health Foundation (Greece)
- Italian Association for Research on Cancer (AIRC) (Italy)
- National Research Council (Italy)
- AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy)
- Dutch Ministry of Public Health, Welfare and Sports (VWS) (the Netherlands)
- Netherlands Cancer Registry (NKR) (the Netherlands)
- LK Research Funds (the Netherlands)
- Dutch Prevention Funds (the Netherlands)
- Dutch ZON (ZorgOnderzoek Nederland) (the Netherlands)
- World Cancer Research Fund (WCRF) (the Netherlands)
- Statistics Netherlands (the Netherlands)
- European Research Council (ERC) (Norway) [ERC-2009-AdG 232997]
- Nordforsk (Norway)
- Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway)
- Health Research Fund (FIS) (Spain)
- Regional Government of Andalucia (Spain) [6236]
- Regional Government of Navarra (Spain) [6236]
- ISCIII RETIC (Spain) [RD06/0020]
- Swedish Cancer Society (Sweden)
- Swedish Scientific Council (Sweden)
- Regional Government of Skane and Vasterbotten (Sweden)
- Cancer Research UK (UK)
- Medical Research Council (UK)
- Stroke Association (UK)
- British Heart Foundation (UK)
- Department of Health (UK)
- Food Standards Agency (UK)
- Wellcome Trust (UK)
- Regional Government of Basque Country (Spain) [6236]
- Regional Government of Murcia (Spain) [6236]
- MRC [MC_UU_12015/1, MR/N003284/1] Funding Source: UKRI
- Cancer Research UK [14136, 16491] Funding Source: researchfish
- Medical Research Council [G0401527, G1000143, MR/N003284/1, MC_U106179471, MC_PC_13048, MC_UU_12015/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10114] Funding Source: researchfish
Ask authors/readers for more resources
We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between prediagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function, and a-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95% confidence intervals (95% CI) for OPN levels in relation to HCC. Receiver operating characteristics curves were constructed to determine the discriminatory accuracy of OPN alone or in combination with other liver biomarkers in the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% increment, ORmultivariable = 1.30; 95% CI, 1.14-1.48). The association was stronger among cases diagnosed within 2 years of follow-up. Adding liver function tests to OPN improved the discriminatory performance for subjects who developed HCC (AUC = 0.86). For cases diagnosed within 2 years, the combination of OPN and AFP was best able to predict HCC risk (AUC = 0.88). The best predictive model for HCC in this low-risk population is OPN in combination with liver function tests. Within 2 years of diagnosis, the combination of OPN and AFP best predicted HCC development, suggesting that measuring OPN and AFP could identify high-risk groups independently of a liver disease diagnosis. (C) 2016 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available